Maria Ajaimy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Ajaimy has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Enver Akalin
Renal Division Montefiore Medical Center, Albert Einstein College of Medicine, Kidney Transplantation Program, Bronx, New York
4 shared publications Enver Akalin
Montefiore Medical Center, Albert Einstein College of Medicine Abdominal Transplant Center, United States
3 shared publicationsAdriana Colovai
2 shared publicationsChristina Savchik
2 shared publicationsGraciela de Boccardo
Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
2 shared publicationsLayla Kamal
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 15845
Increased Treg in Kidney Transplant Recipients With Erythrocytosis
Dear Editors, Erythropoietin (EPO) is a glycoprotein hormone produced predominantly by the kidney in response to hypoxia. While widely known for its hematopoietic role, EPO also exerts immune-modulating effects. In murine transplant models, administration of exogenous EPO prolongs allograft survival by increasing the frequency of regulatory T cell (Treg) and by promoting macrophage polarization towards an anti-inflammatory phenotype. 1 Consistent with these preclinical findings, clinical studies have demonstrated that recombinant EPO administration at the doses normally used to correct anemia administration at the doses normally used to correct anemia in humans enhances both the number and suppressive capabilities of circulating Tregs. 2,3 The immune-modulating effects of endogenous EPO in kidney transplant recipients are less clearly defined. Mice that are EPO deficient are prone to the development of autoimmunity. Patients with chronic kidney disease (CKD) often show intrarenal immune infiltrates, which may be due, at least in part, to the reduced EPO production associated with impaired kidney function. However, CKD patients exhibit multiple inflammatory sources, complicating any direct causal relationship between reduced endogenous EPO levels and intrarenal inflammation.To more rigorously investigate endogenous EPO's immunological impact in humans, we focused on kidney transplant recipients with post-transplant erythrocytosis (PTE), a complication affecting approximately 10-20% of patients, typically within the first two years post-transplant. PTE is characterized by persistently elevated hematocrit levels without ongoing blood loss, hypoxia, or exogenous EPO therapy. 4 We hypothesized that kidney transplant recipients (KTRs) with PTE have high EPO levels and exhibit a distinct immunological profile, characterized by increased circulating Tregs and monocytes with an anti-inflammatory profile.We conducted a cross-sectional study of 14 KTRs with PTE (hematocrit ≥50%) and 19 matched controls without PTE. Using flow cytometry, we quantified circulating immune subsets, including regulatory T cells (Tregs), T cells, B cells, and monocytes. Cytokine levels were assessed by ELISA (see Supplemental methods).Patients with PTE and controls were similar in terms of age (52.9 ± 11.5 vs 52.1 ± 10.5 years, p=0.8), time since transplantation (4.1 ± 2.6 vs 5.6 ± 1.9 years, p=0.08), and kidney function (creatinine 1.4 ± 0.4 vs 1.4 ± 0.5 mg/dL, p=0.8). Consistent with prior reports 5 , the PTE group had a significantly higher proportion of male patients (92.9% vs 52.6%, p=0.02). No significant differences were observed in induction therapy, donorspecific antibodies (DSA), or prior rejection episodes. The distribution of race/ethnicity and underlying kidney disease was comparable between groups (Supplementary Table S1). The use of RAS inhibitors (Renin-Angiotensin system inhibitors) was comparable between PTE patients and controls. Secondary causes of erythrocytosis, including renal artery stenosis and renal tumors, were ruled out in PTE patients. Additional cancer screening was not performed when PTE diagnosis occurred shortly after transplantation, considering the limited time for malignancy development. Patients with PTE had significantly higher serum EPO levels compared to controls (10.5 ± 5.9 vs 6.8 ± 2.5 mIU/mL, p = 0.02) (Supplementary Figure S1A).Tregs, defined phenotypically as CD4⁺CD25⁺CD127 low cells, were significantly higher in patients with PTE compared to controls (3.4% ± 1.3 vs. 2.1% ± 1.3, respectively; p = 0.0096) (Figure 1A-B). We did not observe significant differences in the overall percentages of CD4⁺ and CD8⁺ T cells, or B cells, between PTE patients and controls (Figure 1C). Intracellular cytokine analysis of CD4⁺, CD8 + T cells (including IL-17, IL-4, IFN-γ) and B cells did not reveal significant differences between the two groups.Monocyte percentages did not differ between PTE patients and controls (Figure 1C), but functional analyses revealed that, upon stimulation with LPS (5ng/ml), the percentages of monocytes producing TNF-α (2.3% ± 2.5 vs. 6.6% ± 7.3, respectively; p = 0.043) and IL-6 (8.3% ± 5.5 vs. 12.9% ± 6.4, respectively; p = 0.038) were significantly lower in PTE patients compared to controls. TGF-b production in monocytes did not differ between the two study groups (Figure 1D-F).Plasma levels of TNF-α (22.11 vs. 22.56 pg/mL; p = 0.92) and IL-6 (10.79 vs. 12.65 pg/mL; p = 0.69) were comparable between PTE patients and controls (Supplemental Figure 1B-1C).In summary, we found that elevated EPO levels in KTRs with PTE are associated with increased frequency of circulating Treg and a reduced proinflammatory activation profile in monocytes, despite comparable systemic levels of TNF-α and IL-6. These findings suggest that elevated endogenous EPO may promote a more tolerogenic immune environment after kidney transplantation.Published data by our group and others indicate that EPO promotes the release of active TGF-β by monocytes/macrophages, promoting conversion of naive CD4 + T cells into functional Treg. 1,6 We also showed that EPO induces an anti-inflammatory program in macrophages, although the molecular mechanisms are not fully clear.The combination of increased Tregs and reduced monocyte-derived inflammation in PTE patients raises the intriguing possibility that this cohort of patients may be at lower risk of acute rejection due to the immune-regulatory effects of EPO 7 . On the other hand, the recent evidence that tumors producing EPO have lower chances to be cleared by the anti-tumor immune response, 8 supports studies testing the neoplastic risk of these patients.We also observed a lower rate of DSA in PTE patients (7% vs. 31% in controls). Although this difference did not reach statistical significance, this trend may be...
- 25 November 2025
- Published by Frontiers Media SA in Transplant International
- Vol. 38, 15845
Open AccessIncreased Treg in Kidney Transplant Recipients With Erythrocytosis
Dear Editors, Erythropoietin (EPO) is a glycoprotein hormone produced predominantly by the kidney in response to hypoxia. While widely known for its hematopoietic role, EPO also exerts immune-modulating effects. In murine transplant models, administration of exogenous EPO prolongs allograft survival by increasing the frequency of regulatory T cell (Treg) and by promoting macrophage polarization towards an anti-inflammatory phenotype. 1 Consistent with these preclinical findings, clinical studies have demonstrated that recombinant EPO administration at the doses normally used to correct anemia administration at the doses normally used to correct anemia in humans enhances both the number and suppressive capabilities of circulating Tregs. 2,3 The immune-modulating effects of endogenous EPO in kidney transplant recipients are less clearly defined. Mice that are EPO deficient are prone to the development of autoimmunity. Patients with chronic kidney disease (CKD) often show intrarenal immune infiltrates, which may be due, at least in part, to the reduced EPO production associated with impaired kidney function. However, CKD patients exhibit multiple inflammatory sources, complicating any direct causal relationship between reduced endogenous EPO levels and intrarenal inflammation.To more rigorously investigate endogenous EPO's immunological impact in humans, we focused on kidney transplant recipients with post-transplant erythrocytosis (PTE), a complication affecting approximately 10-20% of patients, typically within the first two years post-transplant. PTE is characterized by persistently elevated hematocrit levels without ongoing blood loss, hypoxia, or exogenous EPO therapy. 4 We hypothesized that kidney transplant recipients (KTRs) with PTE have high EPO levels and exhibit a distinct immunological profile, characterized by increased circulating Tregs and monocytes with an anti-inflammatory profile.We conducted a cross-sectional study of 14 KTRs with PTE (hematocrit ≥50%) and 19 matched controls without PTE. Using flow cytometry, we quantified circulating immune subsets, including regulatory T cells (Tregs), T cells, B cells, and monocytes. Cytokine levels were assessed by ELISA (see Supplemental methods).Patients with PTE and controls were similar in terms of age (52.9 ± 11.5 vs 52.1 ± 10.5 years, p=0.8), time since transplantation (4.1 ± 2.6 vs 5.6 ± 1.9 years, p=0.08), and kidney function (creatinine 1.4 ± 0.4 vs 1.4 ± 0.5 mg/dL, p=0.8). Consistent with prior reports 5 , the PTE group had a significantly higher proportion of male patients (92.9% vs 52.6%, p=0.02). No significant differences were observed in induction therapy, donorspecific antibodies (DSA), or prior rejection episodes. The distribution of race/ethnicity and underlying kidney disease was comparable between groups (Supplementary Table S1). The use of RAS inhibitors (Renin-Angiotensin system inhibitors) was comparable between PTE patients and controls. Secondary causes of erythrocytosis, including renal artery stenosis and renal tumors, were ruled out in PTE patients. Additional cancer screening was not performed when PTE diagnosis occurred shortly after transplantation, considering the limited time for malignancy development. Patients with PTE had significantly higher serum EPO levels compared to controls (10.5 ± 5.9 vs 6.8 ± 2.5 mIU/mL, p = 0.02) (Supplementary Figure S1A).Tregs, defined phenotypically as CD4⁺CD25⁺CD127 low cells, were significantly higher in patients with PTE compared to controls (3.4% ± 1.3 vs. 2.1% ± 1.3, respectively; p = 0.0096) (Figure 1A-B). We did not observe significant differences in the overall percentages of CD4⁺ and CD8⁺ T cells, or B cells, between PTE patients and controls (Figure 1C). Intracellular cytokine analysis of CD4⁺, CD8 + T cells (including IL-17, IL-4, IFN-γ) and B cells did not reveal significant differences between the two groups.Monocyte percentages did not differ between PTE patients and controls (Figure 1C), but functional analyses revealed that, upon stimulation with LPS (5ng/ml), the percentages of monocytes producing TNF-α (2.3% ± 2.5 vs. 6.6% ± 7.3, respectively; p = 0.043) and IL-6 (8.3% ± 5.5 vs. 12.9% ± 6.4, respectively; p = 0.038) were significantly lower in PTE patients compared to controls. TGF-b production in monocytes did not differ between the two study groups (Figure 1D-F).Plasma levels of TNF-α (22.11 vs. 22.56 pg/mL; p = 0.92) and IL-6 (10.79 vs. 12.65 pg/mL; p = 0.69) were comparable between PTE patients and controls (Supplemental Figure 1B-1C).In summary, we found that elevated EPO levels in KTRs with PTE are associated with increased frequency of circulating Treg and a reduced proinflammatory activation profile in monocytes, despite comparable systemic levels of TNF-α and IL-6. These findings suggest that elevated endogenous EPO may promote a more tolerogenic immune environment after kidney transplantation.Published data by our group and others indicate that EPO promotes the release of active TGF-β by monocytes/macrophages, promoting conversion of naive CD4 + T cells into functional Treg. 1,6 We also showed that EPO induces an anti-inflammatory program in macrophages, although the molecular mechanisms are not fully clear.The combination of increased Tregs and reduced monocyte-derived inflammation in PTE patients raises the intriguing possibility that this cohort of patients may be at lower risk of acute rejection due to the immune-regulatory effects of EPO 7 . On the other hand, the recent evidence that tumors producing EPO have lower chances to be cleared by the anti-tumor immune response, 8 supports studies testing the neoplastic risk of these patients.We also observed a lower rate of DSA in PTE patients (7% vs. 31% in controls). Although this difference did not reach statistical significance, this trend may be...
- 22 August 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (7) , 1569-1573
Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience
- 22 August 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (7) , 1569-1573
Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience
- Open Access
- 21 November 2022
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 06 (04) , 1-23
Shifting Pancreas Transplantation Rates and Demographics are the Culmination of Many Strategic Policy Changes
The 2014 Pancreas Allocation System established national qualifying criteria for simultaneous kidney pancreas (SPK) transplantation. The 2019 UNOS Pancreas Transplantation Committee Policy 11.3.B modified these guidelines to expand transplantation. Subsequent effects on recipient demographics have not been studied. We analyzed 81 SPK transplantations performed at our center from June 2014 to December 2020 to compare recipient demographics and outcomes before and after the 11.3.B policy change. National data were also investigated. Significant increases in age (38.9 v 46.4 years; p = 0.01) and c-peptide levels (1.7 v 4.9 ng/ml; p = 0.01) occurred following the removal of BMI and c-peptide requirements. No differences in BMI, outcomes, or complication rates were found. National and center trends showed increasing numbers of recipients with high c-peptide levels and decreasing numbers of recipients with undetectable c-peptide levels. Policy 11.3.B expanded transplantation access while maintaining suitable outcomes, reflecting its intended goals.
- 21 November 2022
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 06 (04) , 1-23
Open AccessShifting Pancreas Transplantation Rates and Demographics are the Culmination of Many Strategic Policy Changes
The 2014 Pancreas Allocation System established national qualifying criteria for simultaneous kidney pancreas (SPK) transplantation. The 2019 UNOS Pancreas Transplantation Committee Policy 11.3.B modified these guidelines to expand transplantation. Subsequent effects on recipient demographics have not been studied. We analyzed 81 SPK transplantations performed at our center from June 2014 to December 2020 to compare recipient demographics and outcomes before and after the 11.3.B policy change. National data were also investigated. Significant increases in age (38.9 v 46.4 years; p = 0.01) and c-peptide levels (1.7 v 4.9 ng/ml; p = 0.01) occurred following the removal of BMI and c-peptide requirements. No differences in BMI, outcomes, or complication rates were found. National and center trends showed increasing numbers of recipients with high c-peptide levels and decreasing numbers of recipients with undetectable c-peptide levels. Policy 11.3.B expanded transplantation access while maintaining suitable outcomes, reflecting its intended goals.
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 99
P062 Characteristics of pre-formed donor specific anti-HLA antibodies associated with their clearance or persistance
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 99
P062 Characteristics of pre-formed donor specific anti-HLA antibodies associated with their clearance or persistance
- 1 September 2016
- Published by Elsevier in Human Immunology
- Vol. 77, 42
P003 Impact of the new kidney allocation system on the transplant rates of highly sensitized patients. A single center experience
- 1 September 2016
- Published by Elsevier in Human Immunology
- Vol. 77, 42
P003 Impact of the new kidney allocation system on the transplant rates of highly sensitized patients. A single center experience
- 20 July 2015
- Published by Wiley in Clinical Transplantation
- Vol. 29 (9) , 781-785
Kidney transplantation in patients with severe preoperative hypertension
Background Severe systemic hypertension (HTN) is a risk factor for perioperative cardiovascular complications; however, its impact at the time of kidney transplantation (KTX) is not well defined. Methods A retrospective cohort study of adult kidney-only transplant recipients between October 2009 and December 2012 was performed to examine outcomes between patients with (n=111) and without (n=98) severe preoperative HTN defined as SBP >180 or DBP> 110mmHg. Results Recipients with severe HTN were older (56.713.0 vs. 53.5 +/- 12.4yr, p=0.07) and significantly more likely to receive an expanded criteria donor kidney (32.7% vs. 12.2%, p=0.02). No patients developed hypertensive crisis, intracranial hemorrhage, or life threatening ventricular arrhythmias within 30d post-transplantation; however, three patients with severe HTN had cardiac events: two with demand ischemia and one with decompensate heart failure. Two patients in the control group had decompensated heart failure. There were no differences between the groups in terms of cardiac event (2.7% vs. 2.0%, p=0.75), one-yr patient survival (98.2% vs. 98.0%, p=0.90) or graft survival (90.1% vs. 92.9%, p=0.48), nadir creatinine >2mg/dL (4.6% vs. 6.2%, p=0.62), length of stay>6d (37.8% vs. 35.7%, p=0.75), and DGF (52.3% vs. 63.3%, p=0.11). Conclusions Our results suggest that severe preoperative HTN should not be considered an absolute contraindication to kidney transplant in patients who are otherwise clinically stable.
- 20 July 2015
- Published by Wiley in Clinical Transplantation
- Vol. 29 (9) , 781-785
Kidney transplantation in patients with severe preoperative hypertension
Background Severe systemic hypertension (HTN) is a risk factor for perioperative cardiovascular complications; however, its impact at the time of kidney transplantation (KTX) is not well defined. Methods A retrospective cohort study of adult kidney-only transplant recipients between October 2009 and December 2012 was performed to examine outcomes between patients with (n=111) and without (n=98) severe preoperative HTN defined as SBP >180 or DBP> 110mmHg. Results Recipients with severe HTN were older (56.713.0 vs. 53.5 +/- 12.4yr, p=0.07) and significantly more likely to receive an expanded criteria donor kidney (32.7% vs. 12.2%, p=0.02). No patients developed hypertensive crisis, intracranial hemorrhage, or life threatening ventricular arrhythmias within 30d post-transplantation; however, three patients with severe HTN had cardiac events: two with demand ischemia and one with decompensate heart failure. Two patients in the control group had decompensated heart failure. There were no differences between the groups in terms of cardiac event (2.7% vs. 2.0%, p=0.75), one-yr patient survival (98.2% vs. 98.0%, p=0.90) or graft survival (90.1% vs. 92.9%, p=0.48), nadir creatinine >2mg/dL (4.6% vs. 6.2%, p=0.62), length of stay>6d (37.8% vs. 35.7%, p=0.75), and DGF (52.3% vs. 63.3%, p=0.11). Conclusions Our results suggest that severe preoperative HTN should not be considered an absolute contraindication to kidney transplant in patients who are otherwise clinically stable.
- 1 September 2014
- Published by Elsevier in Kidney International
- Vol. 86 (3) , 600-609
Increased intragraft rejection–associated gene transcripts in patients with donor-specific antibodies and normal biopsies
- 1 September 2014
- Published by Elsevier in Kidney International
- Vol. 86 (3) , 600-609
Increased intragraft rejection–associated gene transcripts in patients with donor-specific antibodies and normal biopsies